Monkey Pox: Virology, Epidemiology, Vaccines, and Therapeutic Approaches

Shchelkunov, S.N.; Marennikova, S.S.; Moyer, R.W. Chapter: Classification of poxviruses and brief characterization of the genus. In: Orthopovxiruses Pathogenic for Humans; Springer: New York, NY, 2005.

Khodakevich, L.; Jezek, Z.; Kinzanzka, K. Isolation of monkeypox virus from wild squirrel infected in nature. Lancet, 1986, 327(8472), 98-99.
[http://dx.doi.org/10.1016/S0140-6736(86)90748-8] [PMID: 2867342]

Radoni’c, A.; Metzger, S.; Dabrowski, P.W.; Couacy-Hymann, E.; Schuenadel, L.; Kurth, A. Fatal monkeypox in wild-living sooty mangabey, Côte d’Ivoire, 2012. Emerg. Infect. Dis., 2014, 20, 1009-1011.

Jezek, Z.; Grab, B.; Szczeniowski, M.V.; Paluku, K.M.; Mutombo, M. Human monkeypox: Secondary attack rates. Bull. World Health Organ., 1988, 66(4), 465-470.
[PMID: 2844429]

Hutson, C.L.; Olson, V.A.; Carroll, D.S.; Abel, J.A.; Hughes, C.M.; Braden, Z.H.; Weiss, S.; Self, J.; Osorio, J.E.; Hudson, P.N.; Dillon, M.; Karem, K.L.; Damon, I.K.; Regnery, R.L. A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus. J. Gen. Virol., 2009, 90(2), 323-333.
[http://dx.doi.org/10.1099/vir.0.005108-0] [PMID: 19141441]

Ladnyi, I.D.; Jezek, Z.; Fenner, F.; Henderson, D.A.; Arita, I. Chapter: Human monkeypox and other poxvirus infections of man. In: Smallpox and its Eradication; World Health Organization: Geneva, 1988.

Reynolds, M.; McCollum, A.; Nguete, B.; Shongo Lushima, R.; Petersen, B. Improving the care and treatment of monkeypox patients in low-resource settings: Applying evidence from contemporary biomedical and smallpox biodefense research. Viruses, 2017, 9(12), 380.
[http://dx.doi.org/10.3390/v9120380] [PMID: 29231870]

Meyer, H.; Perrichot, M.; Stemmler, M. Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001. J. Clin. Microbiol., 2002, 40, 2919-2921.
[http://dx.doi.org/10.1128/JCM.40.8.2919-2921.2002]

Jezek, Z.; Szczeniowski, M.; Paluku, K.M.; Mutombo, M.; Grab, B. Human monkeypox: Confusion with chickenpox. Acta Trop., 1988, 45(4), 297-307.
[PMID: 2907258]

Hutin, Y.J.F.; Williams, R.J.; Malfait, P.; Pebody, R.; Loparev, V.N.; Ropp, S.L.; Rodriguez, M.; Knight, J.C.; Tshioko, F.K.; Khan, A.S.; Szczeniowski, M.V.; Esposito, J.J. Outbreak of human monkeypox, democratic republic of Congo, 1996 to 1997. Emerg. Infect. Dis., 2001, 7(3), 434-438.
[http://dx.doi.org/10.3201/eid0703.017311] [PMID: 11384521]

Rimoin, A.W.; Kisalu, N.; Kebela-Ilunga, B.; Mukaba, T.; Wright, L.L.; Formenty, P.; Wolfe, N.D.; Shongo, R.L.; Tshioko, F.; Okitolonda, E.; Muyembe, J.J.; Ryder, R.W.; Meyer, H. Endemic human monkeypox, democratic republic of Congo, 2001-2004. Emerg. Infect. Dis., 2007, 13(6), 934-937.
[http://dx.doi.org/10.3201/eid1306.061540] [PMID: 17553242]

Hoff, N.A.; Morier, D.S.; Kisalu, N.K. Varicella coinfection in patients with active monkeypox in the Democratic Republic of the Congo. EcoHealth, 2017, 14, 564-574.
[http://dx.doi.org/10.1007/s10393-017-1266-5]

Formenty, P.; Muntasir, M.O.; Damon, I.; Chowdhary, V.; Opoka, M.L.; Monimart, C.; Mutasim, E.M.; Manuguerra, J.C.; Davidson, W.B.; Karem, K.L.; Cabeza, J.; Wang, S.; Malik, M.R.; Durand, T.; Khalid, A.; Rioton, T.; Kuong-Ruay, A.; Babiker, A.A.; Karsani, M.E.M.; Abdalla, M.S. Human monkeypox outbreak caused by novel virus belonging to Congo Basin clade, Sudan, 2005. Emerg. Infect. Dis., 2010, 16(10), 1539-1545.
[http://dx.doi.org/10.3201/eid1610.100713] [PMID: 20875278]

Jezek, Z.; Szczeniowski, M.; Paluku, K.M.; Mutombo, M. Human monkeypox: Clinical features of 282 patients. J. Infect. Dis., 1987, 156(2), 293-298.
[http://dx.doi.org/10.1093/infdis/156.2.293] [PMID: 3036967]

Likos, A.M.; Sammons, S.A.; Olson, V.A.; Frace, A.M.; Li, Y.; Olsen-Rasmussen, M.; Davidson, W.; Galloway, R.; Khristova, M.L.; Reynolds, M.G.; Zhao, H.; Carroll, D.S.; Curns, A.; Formenty, P.; Esposito, J.J.; Regnery, R.L.; Damon, I.K. A tale of two clades: Monkeypox viruses. J. Gen. Virol., 2005, 86(10), 2661-2672.
[http://dx.doi.org/10.1099/vir.0.81215-0] [PMID: 16186219]

Chen, N.; Li, G.; Liszewski, M.K.; Atkinson, J.P.; Jahrling, P.B.; Feng, Z.; Schriewer, J.; Buck, C.; Wang, C.; Lefkowitz, E.J.; Esposito, J.J.; Harms, T.; Damon, I.K.; Roper, R.L.; Upton, C.; Buller, R.M.L. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology, 2005, 340(1), 46-63.
[http://dx.doi.org/10.1016/j.virol.2005.05.030] [PMID: 16023693]

Sbrana, E.; Newman, P.C.; Xiao, S-Y.; Tesh, R.B. Comparative pathology of north american and central african strains of monkeypox virus in a ground squirrel model of the disease. Am. J. Trop. Med. Hyg., 2007, 76(1), 155-164.
[http://dx.doi.org/10.4269/ajtmh.2007.76.155] [PMID: 17255245]

Mwamba, D.K.; Kebela, B.I.; Shongo, R.L.; Pukuta, E.; Kayembe, N.J.M. Profil épidemiologique du monkeypox en RDC, 2010-2014. Ann. AfricanMed., 2014, 8, 1855-1860.

Durski, K.N.; McCollum, A.M.; Nakazawa, Y.; Petersen, B.W.; Reynolds, M.G. Briand, S Emergence of monkeypox - West and Central Africa, 1970–2017. MMWR, 2018, 67, 306-310.

The current status of human monkeypox: Memorandum from a WHO Meeting. Bull. World Health Organ., 1984, 62(5), 703-713.

Blumberg, S.; Lloyd-Smith, J.O. Inference of R(0) and transmission heterogeneity from the size distribution of stuttering chains. PLOS Comput. Biol., 2013, 9(5), e1002993.
[http://dx.doi.org/10.1371/journal.pcbi.1002993] [PMID: 23658504]

Jackson, R.J.; Ramsay, A.J.; Christensen, C.D.; Beaton, S.; Hall, D.F.; Ramshaw, I.A. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol., 2001, 75(3), 1205-1210.
[http://dx.doi.org/10.1128/JVI.75.3.1205-1210.2001] [PMID: 11152493]

Reynolds, M.G.; Carroll, D.S.; Karem, K.L. Factors affecting the likelihood of monkeypox’s emergence and spread in the post-smallpox era. Curr. Opin. Virol., 2012, 2(3), 335-343.
[http://dx.doi.org/10.1016/j.coviro.2012.02.004] [PMID: 22709519]

Rimoin, A.W.; Mulembakani, P.M.; Johnston, S.C.; Lloyd Smith, J.O.; Kisalu, N.K.; Kinkela, T.L.; Blumberg, S.; Thomassen, H.A.; Pike, B.L.; Fair, J.N.; Wolfe, N.D.; Shongo, R.L.; Graham, B.S.; Formenty, P.; Okitolonda, E.; Hensley, L.E.; Meyer, H.; Wright, L.L.; Muyembe, J.J. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc. Natl. Acad. Sci., 2010, 107(37), 16262-16267.
[http://dx.doi.org/10.1073/pnas.1005769107] [PMID: 20805472]

Tian, D.; Zheng, T. Comparison and analysis of biological agent category lists based on biosafety and biodefense. PLoS One, 2014, 9(6), e101163.
[http://dx.doi.org/10.1371/journal.pone.0101163] [PMID: 24979754]

FSAP. Select Agents Regulations, 42C.F.R. Part 73. 2017. Available from: https://www.ecfr.gov/current/title-42/chapter-I/subchapter-F/part-73

Beer, E.M.; Rao, V.B. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLoS Negl. Trop. Dis., 2019, 13(10), e0007791.
[http://dx.doi.org/10.1371/journal.pntd.0007791] [PMID: 31618206]

Weaver, J.R.; Isaacs, S.N. Monkeypox virus and insights into its immunomodulatory proteins. Immunol. Rev., 2008, 225(1), 96-113.
[http://dx.doi.org/10.1111/j.1600-065X.2008.00691.x] [PMID: 18837778]

Hudson, P.N.; Self, J.; Weiss, S. Elucidating the role of the complement control protein in monkeypox pathogenicity. PLoS One, 2012, 7, e35086.
[http://dx.doi.org/10.1371/journal.pbio.3001769] [PMID: 35998195]

Happi, C.; Adetifa, I.; Mbala, P.; Njouom, R.; Nakoune, E.; Happi, A.; Ndodo, N.; Ayansola, O.; Mboowa, G.; Bedford, T.; Neher, R.A.; Roemer, C.; Hodcroft, E.; Tegally, H.; O’Toole, Á.; Rambaut, A.; Pybus, O.; Kraemer, M.U.G.; Wilkinson, E.; Isidro, J.; Borges, V.; Pinto, M.; Gomes, J.P.; Freitas, L.; Resende, P.C.; Lee, R.T.C.; Maurer-Stroh, S.; Baxter, C.; Lessells, R.; Ogwell, A.E.; Kebede, Y.; Tessema, S.K.; de Oliveira, T. Urgent need for a non-discriminatory and non-stigmatizing nomenclature for monkeypox virus. PLoS Biol., 2022, 20(8), e3001769.
[http://dx.doi.org/10.1371/journal.pbio.3001769] [PMID: 35998195]

Isidro, J.; Borges, V.; Pinto, M.; Sobral, D.; Santos, J.D.; Nunes, A.; Mixão, V.; Ferreira, R.; Santos, D.; Duarte, S.; Vieira, L.; Borrego, M.J.; Núncio, S.; de Carvalho, I.L.; Pelerito, A.; Cordeiro, R.; Gomes, J.P. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat. Med., 2022, 28(8), 1569-1572.
[http://dx.doi.org/10.1038/s41591-022-01907-y] [PMID: 35750157]

Centers for Disease Control and Prevention (CDC). Human monkeypox -- kasai oriental, democratic republic of Congo, February 1996-October 1997. MMWR Morb. Mortal. Wkly. Rep., 1997, 46(49), 1168-1171.
[PMID: 9408046]

Barry, M.; Hnatiuk, S.; Mossman, K.; Lee, S.F.; Boshkov, L.; McFadden, G. The myxoma virus M-T4 gene encodes a novel RDEL-containing protein that is retained within the endoplasmic reticulum and is important for the productive infection of lymphocytes. Virology, 1997, 239(2), 360-377.
[http://dx.doi.org/10.1006/viro.1997.8894] [PMID: 9434727]

Hnatiuk, S.; Barry, M.; Zeng, W.; Liu, L.; Lucas, A.; Percy, D.; McFadden, G. Role of the C-terminal RDEL motif of the myxoma virus M-T4 protein in terms of apoptosis regulation and viral pathogenesis. Virology, 1999, 263(2), 290-306.
[http://dx.doi.org/10.1006/viro.1999.9946] [PMID: 10544103]

Alcamí, A.; Smith, G.L. A soluble receptor for interleukin-1β encoded by vaccinia virus: A novel mechanism of virus modulation of the host response to infection. Cell, 1992, 71(1), 153-167.
[http://dx.doi.org/10.1016/0092-8674(92)90274-G] [PMID: 1394428]

Spriggs, M.K.; Hruby, D.E.; Maliszewski, C.R.; Pickup, D.J.; Sims, J.E.; Buller, R.M.L.; VanSlyke, J. Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell, 1992, 71(1), 145-152.
[http://dx.doi.org/10.1016/0092-8674(92)90273-F] [PMID: 1339315]

Dinarello, C.A. Biologic basis for interleukin-1 in disease. Blood, 1996, 87(6), 2095-2147.
[http://dx.doi.org/10.1182/blood.V87.6.2095.bloodjournal8762095] [PMID: 8630372]

Smith, G.L.; Symons, J.A.; Khanna, A.; Vanderplasschen, A.; Alcamí, A. Vaccinia virus immune evasion. Immunol. Rev., 1997, 159(1), 137-154.
[http://dx.doi.org/10.1111/j.1600-065X.1997.tb01012.x] [PMID: 9416508]

Kotwal, G.J.; Moss, B. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature, 1988, 335(6186), 176-178.
[http://dx.doi.org/10.1038/335176a0] [PMID: 3412473]

Kotwal, G.J.; Isaacs, S.N.; McKenzie, R.; Frank, M.M.; Moss, B. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science, 1990, 250(4982), 827-830.
[http://dx.doi.org/10.1126/science.2237434] [PMID: 2237434]

Isaacs, S.N.; Kotwal, G.J.; Moss, B. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc. Natl. Acad. Sci. USA, 1992, 89(2), 628-632.
[http://dx.doi.org/10.1073/pnas.89.2.628] [PMID: 1731333]

Heymann, D.L.; Szczeniowski, M.; Esteves, K. Re-emergence of monkeypox in Africa: A review of the past six years. Br. Med. Bull., 1998, 54(3), 693-702.
[http://dx.doi.org/10.1093/oxfordjournals.bmb.a011720] [PMID: 10326294]

WHO. Technical advisory group on human monkeypox: Report of a WHO meeting; Geneva, 1999.

Breman, J.G.; Henderson, D.A. Poxvirus dilemmas--monkeypox, smallpox, and biologic terrorism. N. Engl. J. Med., 1998, 339(8), 556-559.
[http://dx.doi.org/10.1056/NEJM199808203390811] [PMID: 9709051]

Jezek, Z.; Fenner, F. Human monkeypox; Karger Publishers: Geneva, 1988.

Centers for Disease Control and Prevention (CDC). Multistate outbreak of monkeypox--Illinois, Indiana, and Wisconsin, 2003. MMWR Morb. Mortal. Wkly. Rep., 2003, 52(23), 537-540.
[PMID: 12803191]

Centers for Disease Control and Prevention (CDC). Update: Multistate outbreak of monkeypox--Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb. Mortal. Wkly. Rep., 2003, 52(24), 561-564.
[PMID: 12816106]

Huhn, G.D.; Bauer, A.M.; Yorita, K.; Graham, M.B.; Sejvar, J.; Likos, A.; Damon, I.K.; Reynolds, M.G.; Kuehnert, M.J. Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin. Infect. Dis., 2005, 41(12), 1742-1751.
[http://dx.doi.org/10.1086/498115] [PMID: 16288398]

Zachary, K.C.; Shenoy, E.S. Monkeypox transmission following exposure in healthcare facilities in nonendemic settings: Low risk but limited literature. Infect. Control Hosp. Epidemiol., 2022, 43(7), 920-924.
[http://dx.doi.org/10.1017/ice.2022.152] [PMID: 35676244]

Adler, H.; Gould, S.; Hine, P.; Snell, L.B.; Wong, W.; Houlihan, C.F.; Osborne, J.C.; Rampling, T.; Beadsworth, M.B.J.; Duncan, C.J.A.; Dunning, J.; Fletcher, T.E.; Hunter, E.R.; Jacobs, M.; Khoo, S.H.; Newsholme, W.; Porter, D.; Porter, R.J.; Ratcliffe, L.; Schmid, M.L.; Semple, M.G.; Tunbridge, A.J.; Wingfield, T.; Price, N.M.; Abouyannis, M.; Al-Balushi, A.; Aston, S.; Ball, R.; Beeching, N.J.; Blanchard, T.J.; Carlin, F.; Davies, G.; Gillespie, A.; Hicks, S.R.; Hoyle, M-C.; Ilozue, C.; Mair, L.; Marshall, S.; Neary, A.; Nsutebu, E.; Parker, S.; Ryan, H.; Turtle, L.; Smith, C.; van Aartsen, J.; Walker, N.F.; Woolley, S.; Chawla, A.; Hart, I.; Smielewska, A.; Joekes, E.; Benson, C.; Brindley, C.; Das, U.; Eyton-Chong, C.K.; Gnanalingham, C.; Halfhide, C.; Larru, B.; Mayell, S.; McBride, J.; Oliver, C.; Paul, P.; Riordan, A.; Sridhar, L.; Storey, M.; Abdul, A.; Abrahamsen, J.; Athan, B.; Bhagani, S.; Brown, C.S.; Carpenter, O.; Cropley, I.; Frost, K.; Hopkins, S.; Joyce, J.; Lamb, L.; Lyons, A.; Mahungu, T.; Mepham, S.; Mukwaira, E.; Rodger, A.; Taylor, C.; Warren, S.; Williams, A.; Levitt, D.; Allen, D.; Dixon, J.; Evans, A.; McNicholas, P.; Payne, B.; Price, D.A.; Schwab, U.; Sykes, A.; Taha, Y.; Ward, M.; Emonts, M.; Owens, S.; Botgros, A.; Douthwaite, S.T.; Goodman, A.; Luintel, A.; MacMahon, E.; Nebbia, G.; O’Hara, G.; Parsons, J.; Sen, A.; Stevenson, D.; Sullivan, T.; Taj, U. van Nipsen tot Pannerden, C.; Winslow, H.; Zatyka, E.; Alozie-Otuka, E.; Beviz, C.; Ceesay, Y.; Gargee, L.; Kabia, M.; Mitchell, H.; Perkins, S.; Sasson, M.; Sehmbey, K.; Tabios, F.; Wigglesworth, N.; Aarons, E.J.; Brooks, T.; Dryden, M.; Furneaux, J.; Gibney, B.; Small, J.; Truelove, E.; Warrell, C.E.; Firth, R.; Hobson, G.; Johnson, C.; Dewynter, A.; Nixon, S.; Spence, O.; Bugert, J.J.; Hruby, D.E. Clinical features and management of human monkeypox: A retrospective observational study in the UK. Lancet Infect. Dis., 2022, 22(8), 1153-1162.
[http://dx.doi.org/10.1016/S1473-3099(22)00228-6] [PMID: 35623380]

US Centers for Disease Control and Prevention. CDC and Texas confirm monkeypox in U.S. traveler. 2021. Available from: https://www.cdc.gov/media/releases/2021/s0716-confirm-monkeypox.html (Accessed April 1, 2023)

US Centers for Disease Control and Prevention. Emergency preparedness and response: Potential exposure to person with confirmed human monkeypox infection-United States. 2021. Available from: https://emergency.cdc.gov/han/2021/han00446.asp (accessed April 1, 2023)

European Centre for Disease Prevention and Control. Monkeypox cases reported in UK and Portugal. 2022. Available from: https://www.ecdc.europa.eu/en/news-events/monkeypox-cases-reported-uk-and-portugal (Accessed April 1, 2023)

Selb, R.; Werber, D.; Falkenhorst, G.; Steffen, G.; Lachmann, R.; Ruscher, C.; McFarland, S.; Bartel, A.; Hemmers, L.; Koppe, U.; Stark, K.; Bremer, V.; Jansen, K. A shift from travel-associated cases to autochthonous transmission with Berlin as epicentre of the monkeypox outbreak in Germany, May to June 2022. Euro Surveill., 2022, 27(27), 2200499.
[http://dx.doi.org/10.2807/1560-7917.ES.2022.27.27.2200499] [PMID: 35801518]

Perez Duque, M.; Ribeiro, S.; Martins, J.V.; Casaca, P.; Leite, P.P.; Tavares, M.; Mansinho, K.; Duque, L.M.; Fernandes, C.; Cordeiro, R.; Borrego, M.J.; Pelerito, A.; de Carvalho, I.L.; Núncio, S.; Manageiro, V.; Minetti, C.; Machado, J.; Haussig, J.M.; Croci, R.; Spiteri, G.; Casal, A.S.; Mendes, D.; Souto, T.; Pocinho, S.; Fernandes, T.; Firme, A.; Vasconcelos, P.; Freitas, G. Ongoing monkeypox virus outbreak, Portugal, 29 April to 23 May 2022. Euro Surveill., 2022, 27(22), 2200424.
[http://dx.doi.org/10.2807/1560-7917.ES.2022.27.22.2200424] [PMID: 35656830]

Rao, A.K.; Petersen, B.W.; Whitehill, F.; Razeq, J.H.; Isaacs, S.N.; Merchlinsky, M.J.; Campos-Outcalt, D.; Morgan, R.L.; Damon, I.; Sánchez, P.J.; Bell, B.P. Use of JYNNEOS (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: Recommendations of the advisory committee on immunization practices - United States, 2022. MMWR Morb. Mortal. Wkly. Rep., 2022, 71(22), 734-742.
[http://dx.doi.org/10.15585/mmwr.mm7122e1] [PMID: 35653347]

Di Giulio, D.B.; Eckburg, P.B. Human monkeypox: An emerging zoonosis. Lancet Infect. Dis., 2004, 4(1), 15-25.
[http://dx.doi.org/10.1016/S1473-3099(03)00856-9] [PMID: 14720564]

Petersen, E.; Kantele, A.; Koopmans, M.; Asogun, D.; Yinka-Ogunleye, A.; Ihekweazu, C.; Zumla, A. Human monkeypox. Infect. Dis. Clin. North Am., 2019, 33(4), 1027-1043.
[http://dx.doi.org/10.1016/j.idc.2019.03.001] [PMID: 30981594]

Centers for Disease Control and Prevention (CDC). Monkeypox virus infection in the united states and other non-endemic countries. 2022. Available from: https://emergency.cdc.gov/han/2022/han00466.asp (Accessed April 14th 2023)

Bunge, E.M.; Hoet, B.; Chen, L.; Lienert, F.; Weidenthaler, H.; Baer, L.R.; Steffen, R. The changing epidemiology of human monkeypox—A potential threat? A systematic review. PLoS Negl. Trop. Dis., 2022, 16(2), e0010141.
[http://dx.doi.org/10.1371/journal.pntd.0010141] [PMID: 35148313]

Centers of Disease Control and Prevention. Biosafety in microbiological and biomedical laboratories. 2023. Available from: https://www.cdc.gov/labs/pdf/CDC-BiosafetyMicrobiologicalBiomedicalLaboratories-2020-P.pdf (Accessed April 14th 2023)

Hammarlund, E.; Lewis, M.W.; Carter, S.V.; Amanna, I.; Hansen, S.G.; Strelow, L.I.; Wong, S.W.; Yoshihara, P.; Hanifin, J.M.; Slifka, M.K. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat. Med., 2005, 11(9), 1005-1011.
[http://dx.doi.org/10.1038/nm1273] [PMID: 16086024]

Hughes, C.; McCollum, A.; Pukuta, E.; Karhemere, S.; Nguete, B.; Shongo Lushima, R.; Kabamba, J.; Balilo, M.; Muyembe Tamfum, J-J.; Wemakoy, O.; Malekani, J.; Monroe, B.; Damon, I.; Reynolds, M. Ocular complications associated with acute monkeypox virus infection, DRC. Int. J. Infect. Dis., 2014, 21, 276-277.
[http://dx.doi.org/10.1016/j.ijid.2014.03.994]

Adalja, A.; Inglesby, T. A novel international monkeypox outbreak. Ann. Intern. Med., 2022, 175(8), 1175-1176.
[http://dx.doi.org/10.7326/M22-1581] [PMID: 35605243]

Grosenbach, D.W.; Honeychurch, K.; Rose, E.A.; Chinsangaram, J.; Frimm, A.; Maiti, B.; Lovejoy, C.; Meara, I.; Long, P.; Hruby, D.E. Oral tecovirimat for the treatment of smallpox. N. Engl. J. Med., 2018, 379(1), 44-53.
[http://dx.doi.org/10.1056/NEJMoa1705688] [PMID: 29972742]

Wittek, R. Vaccinia immune globulin: Current policies, preparedness, and product safety and efficacy. Int. J. Infect. Dis., 2006, 10, 193-201.
[http://dx.doi.org/10.1016/j.ijid.2005.12.001]

James, J.S. Cidofovir recommended for approval for CMV retinitis. AIDS Treat. News, 1996, (244), 6-7.
[PMID: 11363308]

US Food and Drug Administration. FDA approves drug to treat smallpox. 2021. Available from: https://www.fda.gov/drugs/news-events-human-drugs/ (Accessed 15 June 2022)

Lederman, E.R.; Davidson, W.; Groff, H.L.; Smith, S.K.; Warkentien, T.; Li, Y.; Wilkins, K.A.; Karem, K.L.; Akondy, R.S.; Ahmed, R.; Frace, M.; Shieh, W.J.; Zaki, S.; Hruby, D.E.; Painter, W.P.; Bergman, K.L.; Cohen, J.I.; Damon, I.K. Progressive vaccinia: Case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J. Infect. Dis., 2012, 206(9), 1372-1385.
[http://dx.doi.org/10.1093/infdis/jis510] [PMID: 22904336]

US Food and Drug Administration. FDA approves the first drug with an indication for treatment of smallpox. 2018. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-indication-treatment- (Accessed 15 April 2023)

Centers for Disease Control and Prevention. Guidance for tecovirimat use under expanded access investigational new drug protocol during. 2022. Available from: https://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html (Accessed 15 April 2023)

CIDRAP. FDA approves VIG for smallpox shot complications. 2023. Available from: https://www.cidrap.umn.edu/news-perspective/2005/02/fda-approves-vig-smallpox- (Accessed 15 April 2023)

Centers for Disease Control and Prevention. Interim Clinical guidance for the treatment of monkeypox. 2023. Available from: https://www.cdc.gov/poxvirus/monkeypox/treatment.html (Accessed 15 April 2023)

Vora, S.; Damon, I.; Fulginiti, V.; Weber, S.G.; Kahana, M.; Stein, S.L.; Gerber, S.I.; Garcia-Houchins, S.; Lederman, E.; Hruby, D.; Collins, L.; Scott, D.; Thompson, K.; Barson, J.V.; Regnery, R.; Hughes, C.; Daum, R.S.; Li, Y.; Zhao, H.; Smith, S.; Braden, Z.; Karem, K.; Olson, V.; Davidson, W.; Trindade, G.; Bolken, T.; Jordan, R.; Tien, D.; Marcinak, J. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin. Infect. Dis., 2008, 46(10), 1555-1561.
[http://dx.doi.org/10.1086/587668] [PMID: 18419490]

Marty, F.M.; Winston, D.J.; Chemaly, R.F.; Mullane, K.M.; Shore, T.B.; Papanicolaou, G.A.; Chittick, G.; Brundage, T.M.; Wilson, C.; Morrison, M.E.; Foster, S.A.; Nichols, W.G.; Boeckh, M.J. A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant., 2019, 25(2), 369-381.
[http://dx.doi.org/10.1016/j.bbmt.2018.09.038] [PMID: 30292744]

Grimley, M.S.; Chemaly, R.F.; Englund, J.A.; Kurtzberg, J.; Chittick, G.; Brundage, T.M.; Bae, A.; Morrison, M.E.; Prasad, V.K. Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: A randomized placebo-controlled phase II trial. Biol. Blood Marrow Transplant., 2017, 23(3), 512-521.
[http://dx.doi.org/10.1016/j.bbmt.2016.12.621] [PMID: 28063938]

Gazzani, P.; Gach, J.E.; Colmenero, I.; Martin, J.; Morton, H.; Brown, K.; Milford, D.V. Fatal disseminated cowpox virus infection in an adolescent renal transplant recipient. Pediatr. Nephrol., 2017, 32(3), 533-536.
[http://dx.doi.org/10.1007/s00467-016-3534-y] [PMID: 27796621]

Hoy, S.M. Tecovirimat: First global approval. Drugs, 2018, 78(13), 1377-1382.
[http://dx.doi.org/10.1007/s40265-018-0967-6] [PMID: 30120738]

European Medicines Agency. Tecovirimat SIGA. 2022. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tecovirimat-siga (Accessed 17 June 202)

Kinnunen, P.M.; Holopainen, J.M.; Hemmilä, H.; Piiparinen, H.; Sironen, T.; Kivelä, T.; Virtanen, J.; Niemimaa, J.; Nikkari, S.; Järvinen, A.; Vapalahti, O. Severe ocular cowpox in a human, Finland. Emerg. Infect. Dis., 2015, 21(12), 2261-2263.
[http://dx.doi.org/10.3201/eid2112.150621] [PMID: 26583527]

Whitehouse, E.R.; Rao, A.K.; Yu, Y.C.; Yu, P.A.; Griffin, M.; Gorman, S.; Angel, K.A.; McDonald, E.C.; Manlutac, A.L.; de Perio, M.A.; McCollum, A.M.; Davidson, W.; Wilkins, K.; Ortega, E.; Satheshkumar, P.S.; Townsend, M.B.; Isakari, M.; Petersen, B.W. Novel treatment of a vaccinia virus infection from an occupational needlestick - San Diego, California, 2019. MMWR Morb. Mortal. Wkly. Rep., 2019, 68(42), 943-946.
[http://dx.doi.org/10.15585/mmwr.mm6842a2] [PMID: 31647789]

Lindholm, D.A.; Fisher, R.D.; Montgomery, J.R.; Davidson, W.; Yu, P.A.; Yu, Y.C.; Burgado, J.; Wilkins, K.; Petersen, B.W.; Okulicz, J.F. Preemptive tecovirimat use in an active duty service member who presented with acute myeloid leukemia after smallpox vaccination. Clin. Infect. Dis., 2019, 69(12), 2205-2207.
[http://dx.doi.org/10.1093/cid/ciz286] [PMID: 30959520]

US Food and Drug Administration (FDA). Clinical review for new drug application 208627, TPOXX (tecovirimat). 2023. Available from: https://www.accessdata.fda. gov/drugsatfda_docs/nda/2018/208627Orig1s000MedR.pdf (Accessed 15 April 2023)

Rao, A.K.; Schulte, J.; Chen, T.H.; Hughes, C.M.; Davidson, W.; Neff, J.M.; Markarian, M.; Delea, K.C.; Wada, S.; Liddell, A.; Alexander, S.; Sunshine, B.; Huang, P.; Honza, H.T.; Rey, A.; Monroe, B.; Doty, J.; Christensen, B.; Delaney, L.; Massey, J.; Waltenburg, M.; Schrodt, C.A.; Kuhar, D.; Satheshkumar, P.S.; Kondas, A.; Li, Y.; Wilkins, K.; Sage, K.M.; Yu, Y.; Yu, P.; Feldpausch, A.; McQuiston, J.; Damon, I.K.; McCollum, A.M.; Aminu-Alhaji, A.; Andersen, L.; Arduino, M.; Bestul, N.; Bias, M.; Choi, M.J.; Gigante, C.; Harkey, M.; Hendricks, K.; Hercules, Y.; Husain, F.; Ipadeola, O.; Jungerman, R.; Khan, T.; Kharod, G.; Kunkel, A.; MacGurn, A.; Matheny, A.; McCleod, T.; Minhaj, F.S.; Mink, J.; Morgan, C.; Nakazawa, Y.; Newton, D.; Ortega, E.; Priyamvada, L.; Radford, K.; Rehfus, J.; Saleh, M.M.; Townsend, M.B.; Traxler, R.; Whitehill, F.; Wu, X.; Zhao, H.; Carruthers, M.; Gomez, I.; Groppell, S.; Jaramillo, J.; Serinaldi, D.; Serrano, J.; Stringer, J.; Gettings, J.; Pavlick, J.; Retana, J.D.; Stonecipher, S.; Straver, R.; Vilcins, I-M.; Nolen, L.D. Monkeypox in a traveler returning from Nigeria-Dallas, Texas, July 2021. MMWR Morb. Mortal. Wkly. Rep., 2022, 71(14), 509-516.
[http://dx.doi.org/10.15585/mmwr.mm7114a1] [PMID: 35389974]

GlobeNewswire. SIGA announces collaboration with oxford university to support expanded access protocol for use of TPOXX® (Tecovirimat) to treat monkeypox in Central African Republic. 2021. Available from: https://www.globenewswire.com/en/news-release/2021/07/29/2270930/9738/en/SIGA- Announces-Collaboration-with-Oxford-University-to-Support-Expanded-Access-Protocol-for-Use-of-TPOXX-Tecovirimat-To-Treat-Monkeypox-in- Central-African-Republic.html (Accessed 15 April 2023)

Minhaj, F.S.; Ogale, Y.P. Whitehill, F Monkeypox outbreak - nine states, may 2022. MMWR Morb. Mortal. Wkly. Rep., 2022, 71, 764-769.

US Food and Drug Administration. Vaccinia immune globulin intravenous (Human). 2023. Available from: https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/vaccinia-immune-globulin-intravenous-human (Accessed 15 April 2023)

Hopkins, R.J.; Lane, J.M. Clinical efficacy of intramuscular vaccinia immune globulin: A literature review. Clin. Infect. Dis., 2004, 39(6), 819-826.
[http://dx.doi.org/10.1086/422999] [PMID: 15472814]

Centers for Disease Control and Prevention (CDC). Secondary and tertiary transmission of vaccinia virus after sexual contact with a smallpox vaccinee--San Diego, California, 2012. MMWR Morb. Mortal. Wkly. Rep., 2013, 62(8), 145-147.
[PMID: 23446513]

Manenti, A.; Solfanelli, N.; Cantaloni, P.; Mazzini, L.; Leonardi, M.; Benincasa, L.; Piccini, G.; Marchi, S.; Boncioli, M.; Spertilli Raffaelli, C.; Tacconi, D.; Mattiuzzo, G.; Kistner, O.; Montomoli, E.; Trombetta, C.M. Evaluation of Monkeypox- and Vaccinia virus-neutralizing antibodies in human serum samples after vaccination and natural infection. Front. Public Health, 2023, 11, 1195674.
[http://dx.doi.org/10.3389/fpubh.2023.1195674] [PMID: 37415699]

Centers for Disease Control and Prevention. Interim clinical guidance for treatment of monkeypox. 2023. Available from: https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.html (Accessed on 15 April 2023)

Kozlov, M. Monkeypox vaccination begins - can the global outbreaks be contained? Nature, 2022, 606(7914), 444-445.
[http://dx.doi.org/10.1038/d41586-022-01587-1] [PMID: 35676362]

Centers for Disease Control and Prevention. Infection prevention and control of monkeypox in healthcare settings. 2022. Available From: https://www.cdc.gov/poxvirus/monkeypox/clinicians/infection-control-healthcare.html (Accessed on 15 April 2022).